Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
7 hedge funds and large institutions have $3.72M invested in Avenue Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
496% more capital invested
Capital invested by funds: $624K → $3.72M (+$3.09M)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.11M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$62.2K |
| 3 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$14.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$120K |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$49K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $2.68M | +$2.11M | +441 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $379K | -$120K | -25 | -29% |
|
|
BRWA
3
B. Riley Wealth Advisors
Boca Raton,
Florida
| $358K | +$14.4K | +3 | +5% |
|
|
FWM
4
Frontier Wealth Management
Kansas City,
Missouri
| $108K | – | – | – |
|
5
BlackRock
New York
| $98K | – | – | – |
|
|
6
Northern Trust
Chicago,
Illinois
| $79K | +$62.2K | +13 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $17K | +$4.79K | +1 | +50% |
|
|
GPCM
8
Granite Point Capital Management
Boston,
Massachusetts
| – | -$49K | -15 | Closed |
|
|
9
Bank of America
Charlotte,
North Carolina
| – | -$2K | -1 | Closed |
|
ATXI Hedge Fund Activity: Q4 2018 in Review
7 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q4 2018, worth a combined $3.72M — up 496% from $624K a quarter earlier.
Fund positioning in ATXI was balanced in Q4 2018: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $2.11M. The largest seller was Vanguard Group, cutting an estimated $120K.
- 7 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $3.72M of Avenue Therapeutics, Inc. Common Stock stock for Q4 2018, up 496% quarter-over-quarter.
- 2 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q4 2018 and 2 closed out, a net change of 0 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q4 2018 was Opaleye Management, an estimated $2.11M added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q4 2018 was Vanguard Group, an estimated $120K sold.
Based on aggregated 13F filings for Q4 2018.